| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780369 | Gynecologic Oncology | 2018 | 9 Pages |
Abstract
Our data suggests that MMR deficient OC is a unique molecular subgroup, characterized by early stage of diagnosis, MSI phenotype, and increased tumor-infiltrating lymphocytes. These patients may be good candidates for anti-PD-1/PD-L1 therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Xue Xiao, Dandan Dong, Wenjing He, Linhong Song, Qiao Wang, Jun Yue, Lan Xie,